AZTA

Azenta is a life-sciences sample-management and multiomics provider that has been actively reshaping its portfolio since selling the semiconductor automation business for $2.9B in 2022. FY2025 revenue grew just 3.6% to $594M, gross margin held at a respectable 45.5%, and the operating loss narrowed from a deeper hole to -$26.8M (-4.5% margin). The net loss of $55.8M (-9.4% margin) is a 66% improvement YoY, but the business is still unprofitable three years after the semi-cap divestiture, with ROE at -3.3%. The MD&A discloses that in preparing FY2025 statements, management identified errors in previously issued financials and revised FY2023-2025 — concluded immaterial, but it is the kind of disclosure that demands a discount until trust rebuilds, and Risk Factors explicitly flags 'material weaknesses in internal control over financial reporting' as a live concern.

Read the full thesis with Pro →